Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
复制标题
DOI：
10.1016/s0190-9622(03)02099-1
复制
发表时间：
2003-11-01
影响因子：
13.8
通讯作者：
Kinchelow, T
中科院分区：
文献类型：
--
作者：
Ball, RA;Kinchelow, T
背景 Enfuvirtide 是第一种用于治疗 HIV-1 感染的新型抗逆转录病毒药物，称为融合抑制剂。与恩夫韦肽治疗相关的最常见不良事件类型是注射部位反应，发生率高达 98%。许多这些病变都是有症状的。本研究调查了 7 名正在接受恩夫韦肽治疗的 HIV 感染患者发生的注射部位反应。观察结果：所有活检标本均显示出与局部超敏反应一致的炎症反应；这与临床病变的类型无关，并且包括没有临床反应的患者。炎症模式类似于环状肉芽肿和最近描述的间质肉芽肿药物反应。免疫过氧化物酶染色表明，恩夫韦肽沉积区域的炎症和胶原蛋白变化最大。结论：首次描述了人类恩夫韦肽注射部位反应相关的病理变化和临床病理相关性。该信息还为艾滋病毒患者对外来抗原的异常致病反应提供了宝贵的见解。
Background Enfuvirtide is the first of a new class of antiretroviral agents for the treatment of HIV-1 infection, called the fusion inhibitors. The most common type of adverse event associated with enfuvirtide treatment is injection site reactions, occurring in up to 98% of patients. Many of these lesions are symptomatic. This study investigated injection site reactions occurring in 7 patients with HIV infection who were receiving enfuvirtide.Observations: All biopsy specimens revealed an inflammatory response consistent with a localized hypersensitivity reaction; this was regardless of type of clinical lesion and included the patient with no clinical reaction. The pattern of inflammation resembled that of granuloma annulate and the recently described interstitial granulomatous drug reaction. Immunoperoxidase staining indicated that the inflammatory and collagen changes were greatest in areas where enfuvirtide was deposited.Conclusions: The pathologic changes and clinicopathologic correlations associated with injection site reactions in human enfuvirtide recipients have been described for the first time. This information also provides valuable insights into unusual pathogenic response to foreign antigens for patients with HIV.